Enhanced protocol for CD14+ cell enrichment from equine peripheral blood via anti-human CD14 mAb and automated magnetic activated cell sorting.

Authors: Durán M C, Willenbrock S, Carlson R, Feige K, Nolte I, Murua Escobar H

Journal: Equine veterinary journal

DOI: 10.1111/j.2042-3306.2012.00616.x PubMed: 22994596Log in to save

Summary

# Editorial Summary: Enhanced Protocol for CD14+ Cell Enrichment in Equine Peripheral Blood Monocyte-derived dendritic cells (DCs) hold considerable therapeutic promise for equine practitioners, particularly in treating conditions such as sarcoid, owing to their potent antigen-presenting capacity and ability to mount robust immune responses; however, generating these cells from peripheral blood mononuclear cells (PBMCs) has historically been hampered by poor efficiency. Durán and colleagues developed an enhanced enrichment protocol utilising cross-reactive anti-human CD14 monoclonal antibody combined with automated magnetic activated cell sorting (MACS) to isolate CD14+ precursor cells from equine whole blood. The refined methodology significantly improved the yield and purity of CD14+ cells compared with conventional isolation techniques, thereby streamlining the upstream preparation phase for DC differentiation protocols. For veterinary professionals involved in regenerative medicine or immunotherapy, this advancement offers a practical means of obtaining higher-quality starting material, which should reduce culture time and costs whilst enhancing the viability and functionality of the resulting dendritic cell populations. The technical standardisation provided by this protocol strengthens the translational pathway from bench to clinical application in treating equine neoplastic and inflammatory conditions.

Read the full abstract on PubMed

Practical Takeaways

•This improved cell enrichment protocol may facilitate development of dendritic cell-based immunotherapy for equine sarcoid treatment
•The technique optimizes starting material quality for therapeutic cell generation, potentially improving clinical outcomes when dendritic cell therapies are implemented
•Veterinarians considering cellular immunotherapy approaches should be aware that reliable CD14+ enrichment methodology is foundational to efficacy

Key Findings

•CD14+ cells serve as precursor cells for monocyte-derived dendritic cells in horses
•Dendritic cells derived from equine CD14+ cells possess potent antigen-presenting capacity suitable for immunotherapy
•Current generation efficiency of dendritic cells from adherent PBMCs in horses remains suboptimal
•Anti-human CD14 monoclonal antibody combined with automated magnetic cell sorting enables enhanced CD14+ cell enrichment from equine peripheral blood

Conditions Studied

equine sarcoid

Related References

Characterization of respiratory dendritic cells from equine lung tissues.

Lee Yao, Kiupel Matti, Soboll Hussey Gisela(2017)BMC veterinary research

Equine dendritic cells generated with horse serum have enhanced functionality in comparison to dendritic cells generated with fetal bovine serum.

Ziegler Anja, Everett Helen, Hamza Eman, Garbani Mattia, Gerber Vinzenz, Marti Eliane, Steinbach Falko(2016)BMC veterinary research

Phenotype and function of IgE-binding monocytes in equine Culicoides hypersensitivity.

Larson Elisabeth M, Babasyan Susanna, Wagner Bettina(2020)PloS one

Regulatory T cells in early life: comparative study of CD4+CD25high T cells from foals and adult horses.

Hamza Eman, Mirkovitch Jelena, Steinbach Falko, Marti Eliane(2015)PloS one

Equine herpesvirus type 1 (EHV1) induces alterations in the immunophenotypic profile of equine monocyte-derived dendritic cells.

Claessen Christophe, De Lange Valérie, Huang Teng, Ma Guanggang, Osterrieder Nikolaus, Favoreel Herman, Van de Walle Gerlinde R(2016)Veterinary journal (London, England : 1997)